Hematological disorders in children with Down syndrome

Area of Science:

• Hematology
• Pediatric Oncology
• Genetics

Background:

• Hematological abnormalities are frequent in children with Down syndrome (DS).
• DS newborns may experience transient abnormal myelopoiesis (TAM), with a subset progressing to acute myeloid leukemia (ML-DS).
• DS children face a significantly elevated risk of developing acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Purpose of the Study:

• To summarize the hematological complications in children with Down syndrome.
• To highlight the risks and outcomes associated with transient abnormal myelopoiesis and leukemia in DS.
• To emphasize the need for improved, risk-stratified treatments for DS-associated leukemias.

Main Methods:

• Review of existing literature on hematological abnormalities in Down syndrome.
• Analysis of the progression from transient abnormal myelopoiesis to acute myeloid leukemia in DS.
• Comparison of treatment outcomes for leukemia in DS versus non-DS children.

Main Results:

• About 10% of DS newborns present with TAM, with 80% resolving spontaneously.
• A small percentage of DS neonates with TAM can develop acute myeloid leukemia (ML-DS).
• DS-ALL patients generally have poorer prognoses compared to non-DS children.

Conclusions:

• GATA1 mutations serve as reliable markers for minimal residual disease after TAM resolution.
• Chromosome 21 likely plays a critical role in leukemogenesis in Down syndrome.
• Advances in risk-stratified treatment are essential for improving outcomes in DS-ALL patients.